These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21724669)

  • 1. The search for improved antidepressant strategies: is bigger better?
    Coryell W
    Am J Psychiatry; 2011 Jul; 168(7):664-6. PubMed ID: 21724669
    [No Abstract]   [Full Text] [Related]  

  • 2. Placebo group needed for interpretation of combination trial.
    El-Mallakh RS; Kaur G; Lippman S
    Am J Psychiatry; 2010 Aug; 167(8):996; author reply 996-7. PubMed ID: 20693473
    [No Abstract]   [Full Text] [Related]  

  • 3. STAR*D: what have we learned?
    Rush AJ
    Am J Psychiatry; 2007 Feb; 164(2):201-4. PubMed ID: 17267779
    [No Abstract]   [Full Text] [Related]  

  • 4. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-adenosyl methionine (SAMe) augmentation in major depressive disorder.
    Nelson JC
    Am J Psychiatry; 2010 Aug; 167(8):889-91. PubMed ID: 20693465
    [No Abstract]   [Full Text] [Related]  

  • 6. The value of data on suicidality by treatment arm.
    Smith EG
    Am J Psychiatry; 2010 Aug; 167(8):995; author reply 995-6. PubMed ID: 20693471
    [No Abstract]   [Full Text] [Related]  

  • 7. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression.
    Stahl SM
    J Clin Psychiatry; 2009 Nov; 70(11):1493-4. PubMed ID: 20031093
    [No Abstract]   [Full Text] [Related]  

  • 8. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
    Sinyor M; Schaffer A; Smart KA; Levitt AJ; Lanctôt KL; Grysman NH
    J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
    Hashimoto K
    J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
    [No Abstract]   [Full Text] [Related]  

  • 10. Publication bias and the efficacy of antidepressants.
    Mathew SJ; Charney DS
    Am J Psychiatry; 2009 Feb; 166(2):140-5. PubMed ID: 19188290
    [No Abstract]   [Full Text] [Related]  

  • 11. Antidepressant treatment practice in the face of STAR*D and STEP-BD.
    Cassidy F
    Bipolar Disord; 2008 Dec; 10(8):973-4. PubMed ID: 19594512
    [No Abstract]   [Full Text] [Related]  

  • 12. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The modern pharmacopoeia: a return to depressive realism?
    Goldberg JF
    Bipolar Disord; 2008 Dec; 10(8):969-72. PubMed ID: 19594511
    [No Abstract]   [Full Text] [Related]  

  • 15. The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials.
    Mallinckrodt CH; Prucka WR
    Clin Pharmacol Ther; 2010 Nov; 88(5):592-4. PubMed ID: 20959845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for major depressive disorder: an update.
    Rizvi SJ; Kennedy SH
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):285-94. PubMed ID: 22530790
    [No Abstract]   [Full Text] [Related]  

  • 17. No medication without representation? Generalizing from antidepressant clinical efficacy trials to clinical practice.
    Anderson IM
    Psychol Med; 2011 Jul; 41(7):1349-51. PubMed ID: 21439109
    [No Abstract]   [Full Text] [Related]  

  • 18. Does increasing dose improve efficacy in patients with poor antidepressant response: a review.
    Corruble E; Guelfi JD
    Acta Psychiatr Scand; 2000 May; 101(5):343-8. PubMed ID: 10823292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine in the treatment of major depressive disorder.
    Pae CU
    Expert Opin Pharmacother; 2011 Dec; 12(18):2923-8. PubMed ID: 22098230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatments for depression as for other medical disorders.
    Blier P
    Am J Psychiatry; 2012 Jan; 169(1):95; author reply 95-6. PubMed ID: 22223012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.